GC
BPMC

Grace Capital’s Blueprint Medicines BPMC Stock Holding History

Grace Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,696
Closed -$145K – 202
2018
Q4 		$145K Sell
2,696
-273
-9% -$16.6K 0.07% 174
2018
Q3 		$210K Buy
2,969
+273
+10% +$19K 0.08% 157
2018
Q2 		$171K Buy
+2,696
New +$215K 0.07% 171

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Grace Capital's BPMC Position: Q1 2019 in Review

Grace Capital sold out of Blueprint Medicines (BPMC) in Q1 2019, closing a stake of 2,696 shares — an estimated $145K sold.

Grace Capital first reported a position in BPMC in Q2 2018 and held it in 3 quarters. The position peaked at $210K in Q3 2018. 203 funds tracked by Wall St. Rank hold BPMC as of Q1 2019.

  • Grace Capital reported no remaining Blueprint Medicines position as of Q1 2019 after selling out during the quarter.
  • Grace Capital sold 2,696 Blueprint Medicines shares in Q1 2019, an estimated $145K.
  • Grace Capital first reported a position in Blueprint Medicines in Q2 2018 and held it in 3 quarters.
  • Grace Capital's Blueprint Medicines position peaked at $210K in Q3 2018.
  • 203 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2019.

Based on Grace Capital's 13F filing for Q1 2019, filed 15 May 2019.